340 related articles for article (PubMed ID: 19939491)
21. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Joshi AD; Carter JA; Botteman MF; Kaura S
Clin Ther; 2011 Mar; 33(3):291-304.e8. PubMed ID: 21600384
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
Botteman MF; Meijboom M; Foley I; Stephens JM; Chen YM; Kaura S
Eur J Health Econ; 2011 Dec; 12(6):575-88. PubMed ID: 20809091
[TBL] [Abstract][Full Text] [Related]
24. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
25. Skeletal metastases in non-small cell lung cancer: a retrospective study.
Tsuya A; Kurata T; Tamura K; Fukuoka M
Lung Cancer; 2007 Aug; 57(2):229-32. PubMed ID: 17451841
[TBL] [Abstract][Full Text] [Related]
26. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Henk HJ; Kaura S; Teitelbaum A
J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
[TBL] [Abstract][Full Text] [Related]
27. The potential application of zoledronic acid as anticancer therapy in patients with non-small-cell lung cancer.
Mahtani R; Khan R; Jahanzeb M
Clin Lung Cancer; 2011 Jan; 12(1):26-32. PubMed ID: 21273176
[TBL] [Abstract][Full Text] [Related]
28. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
Saad F; Eastham J
Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
[TBL] [Abstract][Full Text] [Related]
29. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
[TBL] [Abstract][Full Text] [Related]
30. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Carter JA; Joshi AD; Kaura S; Botteman MF
Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
[TBL] [Abstract][Full Text] [Related]
31. Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.
Ricciardi S; de Marinis F
Rev Recent Clin Trials; 2009 Sep; 4(3):205-11. PubMed ID: 20028333
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Costa L
Breast; 2007 Dec; 16 Suppl 3():S16-20. PubMed ID: 18032044
[TBL] [Abstract][Full Text] [Related]
33. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Tchekmedyian NS; Chen YM; Saad F
Cancer Invest; 2010 Oct; 28(8):849-55. PubMed ID: 20590447
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
[TBL] [Abstract][Full Text] [Related]
35. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
36. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review.
Hendriks LE; Hermans BC; van den Beuken-van Everdingen MH; Hochstenbag MM; Dingemans AM
J Thorac Oncol; 2016 Feb; 11(2):155-73. PubMed ID: 26718881
[TBL] [Abstract][Full Text] [Related]
37. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
38. Bisphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases.
Price N
Clin Lung Cancer; 2004 Mar; 5(5):267-9. PubMed ID: 15086964
[No Abstract] [Full Text] [Related]
39. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
40. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]